Balaxi Pharmaceuticals Ltd (BALAXI) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 999933, "name": "Balaxi Pharma", "stock_name": "Balaxi Pharma", "full_name": "Balaxi Pharmaceuticals Ltd", "name_url": "stocks-analysis/balaxi-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "24.00", "chg": 0.15, "chgp": "0.63%", "dir": 1, "prev_price": "23.85", "mcapval": "135.00 Cr", "mcap": "Micro Cap", "scripcode": "", "symbol": "BALAXI", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 5, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE618N01022", "curr_date": "Jul 08, 03:30 PM", "curr_time": "18:32 PM", "last_traded_at": "Jul 08, 03:30 PM IST", "bse_nse_vol": 29314, "exc_status": "Active", "traded_date": "Jul 08, 2026", "traded_date_str": "2026 07 08", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/balaxi-pharma-999933-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4093502", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BalaxiPharmaceu_mojoScore_4093502.png", "date": "2026-07-08 10:10:27", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 July 2026, providing investors with the latest perspective on the company’s position." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4075009", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_mojoScore_4075009.png", "date": "2026-06-27 10:10:21", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 27 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4055919", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_mojoScore_4055919.png", "date": "2026-06-16 10:10:35", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 16 June 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Balaxi Pharmaceuticals Ltd Locks at Upper Circuit With 4.81% Gain — Buyers Queue, Sellers Absent", "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-surges-to-upper-circuit-amid-robust-buying-pressure-4054171", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_stocks_hitting_upper_circuit_4054171.png", "date": "2026-06-15 10:00:50", "description": "At Rs 23.99, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Balaxi Pharmaceuticals Ltd locked at its upper circuit of 4.81% on 15 Jun 2026, with buyers queuing and no sellers willing to part with shares." }, { "title": "Balaxi Pharmaceuticals Declines 7.36% Amid Earnings Slump and Valuation Concerns", "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-declines-736-amid-earnings-slump-and-valuation-concerns-4052060", "imagepath": "", "date": "2026-06-13 16:21:11", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>1 June:</strong> Sharp decline in quarterly financial performance reported</p>\n <p><strong>2 June:</strong> Valuation shifts to very expensive amid weak returns</p>\n <p><strong>5 June:</strong> Week closes at Rs.24.28 (-7.36%)</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.26.21</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.24.28</div><div class=\"stat-change negative\">-7.36%</div></div>\n <div class=\"stat-item\"><div class=\"..." }, { "title": "Balaxi Pharmaceuticals Ltd Valuation Shifts to Very Expensive Amidst Weak Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-valuation-shifts-to-very-expensive-amidst-weak-returns-4029449", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_valuationdot_4029449.png", "date": "2026-06-02 08:04:36", "description": "Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from a previously attractive valuation to being classified as very expensive. This transformation is underscored by a sharp rise in its price-to-earnings (P/E) ratio and a contrastingly low price-to-book value (P/BV), raising questions about the stock’s price attractiveness relative to its historical and peer benchmarks." }, { "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4026014", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_mojoScore_4026014.png", "date": "2026-06-01 10:10:51", "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook." }, { "title": "Balaxi Pharmaceuticals Ltd Reports Sharp Decline in Quarterly Financial Performance Amid Negative Trend Shift", "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-ltd-reports-sharp-decline-in-quarterly-financial-performance-amid-negative-trend-shift-4024999", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_fintrenddot_4024999.png", "date": "2026-06-01 08:00:52", "description": "Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. The company’s recent quarterly results reveal a marked contraction in revenue and profitability, signalling a shift from a previously flat financial trend to a distinctly negative trajectory." }, { "title": "Are Balaxi Pharmaceuticals Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-balaxi-pharmaceuticals-ltd-latest-results-good-or-bad-4023875", "imagepath": "", "date": "2026-05-30 19:49:04", "description": "Balaxi Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.61 crores, which represents a substantial decline of 92.94% year-on-year. This decline is indicative of a broader trend, as the company has faced three consecutive quarters of revenue contraction, with Q4 FY26 revenue at ₹70.71 crores, down 7.29% from the previous year.\n\nThe operating margin has also experienced a dramatic contraction, falling to 0.17% from 16.47% year-on-year. This sharp decline highlights severe issues within the company's cost structure and operational efficiency. Furthermore, the operating profit before depreciation, interest, and tax (excluding other income) plummeted to just ₹0.12 crores, marking a staggering 99.04% decline compared to the same quarter last year.\n\nThe company's return on equity (ROE) has deteriorated to 6.09%, significant..." } ], "total": 119, "sid": "999933", "stock_news_url": "https://www.marketsmojo.com/news/balaxi-pharmaceuticals-999933" }, "announcements": [ { "details": "Balaxi Ventures Limited has informed the Exchange regarding Resignation of Mr Nidhin Jose as Chief Financial Officer of the company w.e.f. November 30, 2019.", "source": "NSE", "caption": "Balaxi Ventures Limited - Resignation", "datetime": "21-Nov-2019" }, { "details": "Balaxi Ventures Limited has informed the Exchange regarding Statement of deviation(s) or variation(s) under Reg. 32 of SEBI (LODR) Regulations 2015", "source": "NSE", "caption": "Balaxi Ventures Limited - Statement of deviation(s) or variation(s) under Reg. 32", "datetime": "30-Oct-2019" }, { "details": "Balaxi Ventures Limited has informed the Exchange regarding Board meeting held on October 29, 2019.", "source": "NSE", "caption": "Balaxi Ventures Limited - Outcome of Board Meeting", "datetime": "29-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Balaxi Pharmaceuticals Ltd has declared <strong>5%</strong> dividend, ex-date: 01 Jul 22", "dt": "2022-07-01", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Balaxi Pharmaceuticals Ltd has announced <strong>2:10</strong> stock split, ex-date: 30 May 24", "dt": "2024-05-30", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

1 June: Sharp decline in quarterly financial performance reported

2 June: Valuation shifts to very expensive amid weak returns

5 June: Week closes at Rs.24.28 (-7.36%)

Read full news article

Balaxi Pharmaceuticals Ltd Valuation Shifts to Very Expensive Amidst Weak Returns

2026-06-02 08:04:36

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from a previously attractive valuation to being classified as very expensive. This transformation is underscored by a sharp rise in its price-to-earnings (P/E) ratio and a contrastingly low price-to-book value (P/BV), raising questions about the stock’s price attractiveness relative to its historical and peer benchmarks.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-06-01 10:10:51

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 June 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Read full news article

Balaxi Pharmaceuticals Ltd Reports Sharp Decline in Quarterly Financial Performance Amid Negative Trend Shift

2026-06-01 08:00:52

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant deterioration in its financial performance for the quarter ended March 2026. The company’s recent quarterly results reveal a marked contraction in revenue and profitability, signalling a shift from a previously flat financial trend to a distinctly negative trajectory.

Read full news article

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

2026-05-30 19:49:04

Balaxi Pharmaceuticals Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a net profit of ₹0.61 crores, which represents a substantial decline of 92.94% year-on-year. This decline is indicative of a broader trend, as the company has faced three consecutive quarters of revenue contraction, with Q4 FY26 revenue at ₹70.71 crores, down 7.29% from the previous year. The operating margin has also experienced a dramatic contraction, falling to 0.17% from 16.47% year-on-year. This sharp decline highlights severe issues within the company's cost structure and operational efficiency. Furthermore, the operating profit before depreciation, interest, and tax (excluding other income) plummeted to just ₹0.12 crores, marking a staggering 99.04% decline compared to the same quarter last year. The company's return on equity (ROE) has deteriorated to 6.09%, significant...

Read full news article